Optimizing Immunotherapy in Advanced Non-Small Cell Lung Cancer – Targeted Oncology
Targeted Oncology |
Optimizing Immunotherapy in Advanced Non-Small Cell Lung Cancer
Targeted Oncology This year’s American Association for Cancer Research (AACR) Annual Meeting was the backdrop for pivotal data that may significantly change the standard of care in advanced lung cancer, the deadliest cancer worldwide and responsible for an estimated … |
Targeted Oncology |
Optimizing Immunotherapy in Advanced Non-Small Cell Lung Cancer
Targeted Oncology This year’s American Association for Cancer Research (AACR) Annual Meeting was the backdrop for pivotal data that may significantly change the standard of care in advanced lung cancer, the deadliest cancer worldwide and responsible for an estimated … Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients?Medscape |
Streetwise Reports |
Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Streetwise Reports In this interview with The Life Sciences Report, IMV Inc.’s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of … |
Rare Disease Report |
FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell … FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell DiseaseMD Magazine |
Rare Disease Report |
FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell … FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell DiseaseMD Magazine |